Novo shares jump 6% as Wegovy sales impress
ITF Team3 min read
Novo Nordisk shares rose 6% on 3/11/2026 after Wegovy sales hit 5.4 bn DKK, beating forecasts and prompting an outlook upgrade to +/-2% growth.
Key takeaways
- Novo Nordisk shares gained more than 6% in early trading on 3/11/2026.
- Q3 sales reached 79.2 bn DKK, up 4% YoY at constant exchange rates.
- Wegovy revenue was 5.4 bn DKK, exceeding the 4.5 bn DKK consensus.
- Adjusted revenue and operating profit growth outlook was revised to –2% to +2% at constant rates.
Novo Nordisk reported a stronger‑than‑expected third‑quarter on 3 November 2026, sending Copenhagen‑listed shares up more than 6% in early trading. The boost came from Wegovy, the company’s weekly GLP‑1 obesity injection, which posted sales of 5.4 bn DKK, comfortably above the 4.5 bn DKK analysts had forecast. The surprise helped the Danish drugmaker lift its full‑year outlook, now expecting adjusted revenue and operating profit growth of –2% to +2% on a constant‑currency basis.
Quarterly performance beats estimates
Total sales for the quarter reached 79.2 bn DKK, a 4% year‑on‑year increase when foreign‑exchange effects are stripped out. This topped FactSet’s consensus of 73.6 bn DKK. Adjusted EBIT came in at 31.7 bn DKK versus the 28.6 bn DKK expected, underscoring the profitability of the GLP‑1 portfolio. In addition to Wegovy, the injectable diabetes drug Ozempic generated 29.7 bn DKK, while the combined injectable Wegovy sales (including the newly launched version) amounted to 20.4 bn DKK, all above market expectations.
The earnings beat reflects continued global demand for GLP‑1 medicines, a segment that now serves roughly 10% of the U.S. population. Novo’s ability to grow sales despite a competitive environment, where Eli Lilly has overtaken it in the United States, is a key narrative for investors.
Why the outlook was upgraded
Previously, Novo had projected full‑year revenue and profit to be flat to –6% on a constant‑currency basis after an August upgrade. The stronger Q3 results prompted the company to narrow that range to –2% to +2%. Management highlighted that the Wegovy launch earlier in the year is gaining traction and that pipeline candidates targeting obesity‑related comorbidities such as heart disease, kidney disease, sleep apnea and arthritis could add future upside.
CEO Mike Doustdar cautioned that a single quarter does not constitute a full turnaround, but he said the progressive improvement in guidance throughout 2026 gives confidence that the recovery path is solidifying. The comment was aimed at restoring investor trust after a 17% YTD decline and an 8% single‑day drop in September when the company’s post‑Wegovy growth plan was deemed unclear.
Read also: Bitcoin defends $76k lows as analysts cite political gridlock
Leadership change and market reaction
Alongside the earnings release, Novo announced that CFO Karsten Munk Knudsen will step down at the end of 2026 after 27 years with the firm. He will be succeeded by Luigi La Corte, currently CFO of Galderma. The transition is viewed as a move to bring fresh financial stewardship as the company navigates a more competitive GLP‑1 landscape.
Investors appear to have rewarded the combined news of better‑than‑expected sales and a clearer outlook, despite the lingering concerns about market share loss to Eli Lilly, which recently raised its own guidance on strong demand for Mounjaro and Zepbound.
What to watch next
Traders will monitor upcoming U.S. prescription data for Wegovy and Ozempic, as well as the rollout of next‑generation obesity drugs that aim to treat related diseases. Any indication of pricing pressure or supply constraints could affect margins.
Analysts also keep an eye on the September‑December 2026 earnings window, where Novo will need to demonstrate sustained growth to close the YTD performance gap. Key technical levels for the stock sit near 600 DKK resistance and 540 DKK support, based on recent price action.
- Q3 sales: 79.2 bn DKK (+4% YoY)
- Wegovy sales: 5.4 bn DKK vs. 4.5 bn DKK consensus
- Adjusted EBIT: 31.7 bn DKK vs. 28.6 bn DKK estimate
- Outlook revised to –2% to +2% growth at constant rates
Frequently asked questions
What caused Novo Nordisk shares to rise 6% on 3 Nov 2026?
The share jump was triggered by Wegovy sales of 5.4 bn DKK, which beat the 4.5 bn DKK consensus, and by an earnings beat that lifted the full‑year revenue and profit outlook to a –2% to +2% range on a constant‑currency basis.
How did Novo's third‑quarter revenue compare with expectations?
Novo reported 79.2 bn DKK in Q3 revenue, a 4% year‑on‑year increase at constant exchange rates, exceeding FactSet’s estimate of 73.6 bn DKK.
Official data sources
Related news
- Bitcoin defends $76k lows as analysts cite political gridlock
- What i am watching today – nasdaq 100, platinum, eur/chf, and aud/jpy
- Coinbase price target cut by 50% as post‑earnings sell‑off widens
- S&P 500 history shows strong post‑midterm performance
More from ITF
This article is compiled from international market news for information only. It is not investment advice.